A randomized, double-blind, placebo-controlled phase I/II evaluation of 9-[2-(bispivaloyloxy-methyl) phosphonyl-methoxy]adenine (bis-POM PMEA), an orally bioavailable prodrug of the anti-HIV nucleotide, PMEA: PA Barditch-Crovo, J Toole, H Burgee, M Wachsman, D Ebeling, KC Cundy, HS Jaffe, PS Lietman. The Johns Hopkins University, Baltimore MD and Gilead Sciences, Inc., Foster City, CA